Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina Venetia Long, Ana Maria Arance, Jean‐Jacques Grob, Laurent Mortier, ADIL I. DAUD, Matteo Salvatore Carlino, Catriona M. McNeil, Michal Lotem, James Larkin, Paul C. Lorigan, Bart Neyns, Christian U. Blank, Omid Hamid, Christine Mateus, Ronnie Shapira‐Frommer, Michele Kosh, Nageatte Ibrahim, Scot Ebbinghaus, Antoni Ribas
New England Journal of Medicine · 2015 · 6,034 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Robert, C., Schachter, J., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., Larkin, J., Lorigan, P. C., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira‐Frommer, R., Kosh, M., Zhou, H., … Ribas, A. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521–2532. https://doi.org/10.1056/nejmoa1503093
In text: (Robert et al., 2015)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Related papers
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer2016
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma2010
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review2017
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer2012
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer2016
Metadata from OpenAlex (CC0). Citations are generated from the published record.